Renal effects of molecular targeted therapies in oncology: a review by the Cancer and the Kidney International Network (C-KIN)Vincent Launay‐Vacher, Ben Sprangers, Matti Aapro et al.|Annals of Oncology|2015Cited by 79
Phase I and Pharmacokinetic Study of Erlotinib for Solid Tumors in Patients With Hepatic or Renal Dysfunction: CALGB 60101Antonius A. Miller, Mark J. Ratain, Daryl J. Murry et al.|Journal of Clinical Oncology|2007Cited by 68
Clinical Cancer Advances 2012: Annual Report on Progress Against Cancer From the American Society of Clinical OncologyBruce J. Roth, Nicholas J. Vogelzang, Lada Krilov et al.|Journal of Clinical Oncology|2012Cited by 63
Improving Cancer Care for Patients With CKD: The Need for Changes in Clinical TrialsBen Sprangers, Kenar D. Jhaveri, Mark A. Perazella et al.|Kidney International Reports|2022Cited by 25
Polypharmacy, potentially inappropriate medications, and chemotherapy-related adverse events among older adults with cancer.Ronald J. Maggiore, Arti Hurria, CP Gross et al.|Journal of Clinical Oncology|2011Cited by 11